FTT PET/CT in Pancreatic Neuroendocrine Tumors

Conditions

• Neuroendocrine Carcinoma Metastatic
• Pancreatic Tumors

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• [18F]FluorThanatrace — DRUG
  Intravenous injection of ≤ 12 mCi of \[18F\]FTT for whole-body PET CT dynamic imaging and subsequent static scan.

Study Details

A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.

Key Dates

Start date

Oct 1, 2025

Status verified

Jan 2026

Primary completion

Sep 30, 2027

Completion

Sep 30, 2027

Study Design

Enrollment

12 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Arms

• Experimental: 18F-FTT PET/CT
  Eligible patients will undergo study imaging using a whole-body PET CT scanner25. Dynamic imaging will be obtained beginning immediately prior to the intravenous injection of ≤ 12 mCi of \[18F\]FTT (a range of 8-12 mCi is anticipated for most dose, a lower dose may be injected if quality images will still be able to be acquired) for a total of approximately 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PIs discretion. Images will analyzed according to already established image analysis methods, noting extensive experience with \[18F\]FTT17-21. Kinetic analysis will be performed on the dynamic data akin to prior work in ovarian cancer.

Primary Outcome Measure

[18F]FTT SUV in PanNETS [ Time Frame: Baseline ]

Central Contacts

• Erin K Schubert, MS
  215-573-6569
  [email protected]

Locations (1)

Find similar trials in Philadelphia, PA